Novartis Acquires Monte Rosa's Drug Candidates
This is a U.S. news story, published by Yahoo Finance, that relates primarily to Monte Rosa news.
U.S. news
For more U.S. news, you can click here:
more U.S. newsMonte Rosa news
For more Monte Rosa news, you can click here:
more Monte Rosa newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Swiss pharmaceutical giant Novartis. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Monte Rosa Therapeutics news, Novartis news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
many major pharmaceutical companiesReuters
•Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs
79% Informative
Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates.
Monte Rosa will also be eligible for future payments of up to $2.1 billion as well as royalties on net sales outside the U.S. Shares of Monte Rosa surged 32% to $ 6.46 in premarket trade.
VR Score
89
Informative language
96
Neutral language
41
Article tone
formal
Language
English
Language complexity
68
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links